Mark R. Thompson

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ.

InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA.

SkinMedica, Inc. is a specialty skin care pharmaceutical company. It develops, acquires, and commercializes products for treatment of dermatologic conditions and improvement of skin appearance. It markets and sells to physicians, with a focus on aesthetics, both prescriptions and non-prescription skin care products. SkinMedica was founded in May 1999. Its company headquarters are located in Carlsbad, California. Company already EXT. Filed in HOL tracker.

Elan Biopharmaceuticals, Inc. distributes drugs and pharmaceuticals. It currently distributes three concentrated morphine sulfate oral solutions which include RoxanolT CII, Roxanol-TT CII and Roxanol 100T CII. Elan Biopharmaceuticals is located in San Diego, CA.